Related Experiment Videos
Effects of lovastatin on high-density lipoprotein subfractions in hypercholesterolemic patients with peripheral
M Tilly-Kiesi1, S P Mattila, M J Tikkanen
1First Department of Medicine, University of Helsinki, Finland.
Insights
Lovastatin treatment increased high-density lipoprotein (HDL) particles, particularly HDL2, in patients with hyperlipoproteinemia. This suggests lovastatin therapy boosts HDL levels by increasing particle number rather than cholesterol content.
Area of Science:
- Cardiology
- Lipid Metabolism
- Pharmacology
Background:
- Peripheral vascular disease (PVD) and hyperlipoproteinemia are significant cardiovascular risk factors.
- High-density lipoproteins (HDL) play a crucial role in reverse cholesterol transport.
- Understanding the impact of lipid-lowering drugs on HDL subfractions is vital for cardiovascular health management.
Purpose of the Study:
- To investigate the effects of lovastatin on HDL subfractions (HDL2 and HDL3) in patients with PVD and hyperlipoproteinemia.
- To determine whether lovastatin treatment leads to cholesterol enrichment or an increase in HDL particle number.
- To compare the effects of lovastatin on HDL subfractions in patients with type IIa versus type IIb hyperlipoproteinemia.
Main Methods:
- A study involving 34 patients with severe peripheral vascular disease and type IIa or IIb hyperlipoproteinemia.
- Utilized density gradient ultracentrifugation to analyze HDL subfractions (HDL2 and HDL3).
- Measured concentrations of cholesterol, total lipid, apolipoprotein AI (apoAI), and apolipoprotein AII (apoAII) in HDL subfractions before and after lovastatin treatment.
Main Results:
- Lovastatin treatment significantly increased concentrations of cholesterol, total lipid, apoAI, and apoAII in HDL2.
- Percentage increases in HDL2 components were more pronounced in patients with type IIb hyperlipoproteinemia compared to type IIa.
- The apoAI/apoAII weight ratio in HDL2 increased, suggesting a shift in HDL particle composition or number.
Conclusions:
- Lovastatin therapy appears to increase serum HDL-cholesterol by increasing the number of HDL particles, rather than by enriching existing particles with cholesterol.
- The observed changes in HDL subfractions were more significant in patients with type IIb hyperlipoproteinemia.
- These findings contribute to understanding the mechanisms by which statins impact lipoprotein metabolism and cardiovascular risk.
Abstract:
The effects of lovastatin treatment on high-density lipoprotein subfractions (HDL2 and HLD3) were investigated in 34 patients with severe peripheral vascular disease and type IIa or type IIb hyperlipoproteinemia by use of a density gradient ultracentrifugation method. Lovastatin therapy caused greater percentage changes in HDL2 than in HDL3. In HDL2 the increases of cholesterol, total lipid, apolipoprotein AI (apoAI) and apolipoprotein AII (apoAII) concentrations were 23% (p < 0.05), 28% (p < 0.01), 24% (p < 0.01) and 11% (p < 0.01), respectively, in subjects with the type IIa phenotype. In patients with the type IIb phenotype the corresponding increases were 42% (p < 0.01), 44% (p < 0.01), 38% (p < 0.01) and 21% (p < 0.05), respectively. The apoAI/apoAII weight ratio in HDL2 rose by 11% and by 13% in type IIa and type IIb patients, respectively. The present results suggest that during lovastatin treatment the slight increase in serum HDL-cholesterol concentration was due, not to cholesterol enrichment by high-density lipoproteins, but more probably to an increase of the number of HDL particles. The observed changes were more pronounced in type IIb than in type IIa patients.